During Michaelmas Term, OxTalks will be moving to a new platform (full details are available on the Staff Gateway).
For now, continue using the current page and event submission process (freeze period dates to be advised).
If you have any questions, please contact halo@digital.ox.ac.uk
Natural Killer (NK) cells are a subset of innate lymphocytes that play a major role in the immune response against tumors. During my post-doctoral training, I discovered two mechanisms employed by tumor cells to evade NK cell-mediated immune surveillance.
Initially, we found that NK cells infiltrating tumors with low expression of MHC class I molecules became functionally anergic. NK cell anergy was associated with impaired signaling downstream of activating receptors and was reverted by treatment with pro-inflammatory cytokines. Notably, in tumors with anergic NK cells, cytokine treatment had an impressive therapeutic effect resulting in increased mouse survival (Ardolino et al., JCI, 2014).
In a second study, we discovered that NK cells in several mouse tumor models expressed the checkpoint inhibitory receptor PD-1. PD-1 inhibited the NK cell response to tumor cells expressing the PD-1 ligand PD-L1. Importantly, mice treated with a PD-1 blocking antibody responded dramatically to the treatment, with the response completely depending on the NK cells (Ardolino et al., manuscript in preparation). As PD-1 is a major target of cancer immunotherapy, this discovery is of the outmost importance and provides new insight on the successful outcome of checkpoint blockade.
During the seminar, I will present key data concerning these two studies. In addition, I will briefly overview my plan as an independent investigator, presenting some preliminary data supporting the proposal.